-Lower VAF of recurrent AML/MDS-associated mutations-Higher T cell to AML ratio-Increased T cell to myeloid ratio-Donor-derived myeloid cells present at higher % in responders-Higher circulating expression of CCL17, CXCL1, CXCL5, EGF, LAMP3, and PDGF subunit B. This evidence concerns the gene CXCL5 and acute myeloid leukemia.